Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Cullinan Therapeutics announced positive Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, showing clinical benefit including remissions in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following single target doses. The drug demonstrated deep, dose-dependent B cell depletion with a favorable safety profile. The company will present additional data and host an Immunology Day on June 10 to discuss CLN-978 and initial data for velinotamig, a BCMAxCD3 T cell engager.